Skip to main content
NCBI home page
Taylor & Francis - PMC COVID-19 Collection logoLink to Taylor & Francis - PMC COVID-19 Collection
. 2005 Apr 20;5(3):369–380. doi: 10.1517/14712598.5.3.369

The role of reverse genetics in the development of vaccines against respiratory viruses

GA Marsh a, GA Tannock b
PMCID: PMC7105756  PMID: 15833074

Abstract

Despite their significance, the only available vaccines against respiratory viruses are those for the prevention of influenza. Attempts have been made to produce vaccines against other respiratory viruses using traditional techniques, but have met with little success. Reverse genetics, although still a r-elatively new tool for the manipulation of negative-strand RNA viruses, has great potential for the preparation of vaccines against many of the common respiratory viruses. In the preparation of live vaccines, reverse genetics s-ystems allow the direct modification of the specific regions in the genomes of negative-stranded RNA viruses concerned with attenuation; the ultimate goal is the introduction of site-specific mutations through a cDNA intermediate in order to develop strains with the requisite attenuation, antigenic and growth properties needed in a vaccine. These techniques can also be used to disarm potentially highly pathogenic viruses, such as emerging H5N1 avian influenza viruses, in order to facilitate large-scale preparation of viruses for use in inactivated vaccines under conditions of manufacturing safety. Before these vaccines become available, residual issues concerned with intellectual property rights to the technology and its application will need to be resolved.

Keywords: respiratory, reverse genetics, RNA, vaccine, virus

Bibliography

Papers of special note have been highlighted as either of interest(•)or of considerable interest(••)to readers.

  • 1.LEDER K, SINCLAIR MI, MITAKAKIS TZ, HELLARD ME, FORBES A: A community-based study of respiratory episodes in Melbourne, Australia. Aust. NZ. J. Public Health (2003) 27(4):399–404. [DOI] [PubMed] [Google Scholar]
  • 2.ENARSON DA, CHRETIEN J: Epidemiology of respiratory infectious diseases. Curr. Opin. Pulm. Med. (1999) 5(3):128–135. [DOI] [PubMed] [Google Scholar]
  • 3.DOUGLAS RM: Respiratory tract infections as a public health challenge. Clin. Infect. Dis. (1999) 28(2):192–194. [DOI] [PubMed] [Google Scholar]
  • 4.ZAMAN K, BAQUI AH, YUNUS M et al.: Acute respiratory infections in children: a community-based longitudinal study in rural Bangladesh. J. Trop. Pediatr. (1997) 43(3):133–137. [DOI] [PubMed] [Google Scholar]
  • 5.SINGH MP, NAYAR S: Magnitude of acute respiratory infections in under five children. J. Commun. Dis. (1996) 28(4):273–278. [PubMed] [Google Scholar]
  • 6.MAKELA MJ, PUHAKKA T, RUUSKANEN O et al.: Viruses and bacteria in the etiology of the common cold. J. Clin. Microbiol (1998) 36(2):539–542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.WRIGHT PF, WEBSTER RG: Orthomyxoviruses. In: Fields Virology. Fields B, Knipe DM, Howley PM (Eds), Lippincott, Williams and Wilkins, Philadelphia, USA (2001).
  • 8.COUCH RB, KEITEL WA, GATE TR: Improvement of inactivated influenza virus vaccines. J. Infect. Dis. (1997) 176\(Suppl. 1):538–544. [DOI] [PubMed] [Google Scholar]
  • 9.BELSHE RB, MENDELMAN PM, TREANOR J et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl. J. Med. (1998) 338(20):1405–1412. [DOI] [PubMed] [Google Scholar]
  • 10.FENTON RJ, JENNINGS R, POTTER CW: Differential response of ferrets to infection with virulent and avirulent influenza viruses: A possible marker of virus attenuation. Arch. Virol (1977) 55:55–66. [DOI] [PubMed] [Google Scholar]
  • 11.JOHNSTON PR, FELDMAN S, THOMPSON JM, MAHONEY JD, WRIGHT PE: Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J. Infect. Dis. (1986) 154:121–127. [DOI] [PubMed] [Google Scholar]
  • 12.KENDAL AP: Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. Epidemiol (1997) 13:591–609. [DOI] [PubMed] [Google Scholar]
  • 13.POTTER CW: Attenuated influenza virus vaccines. Med. Wrol. (1994) 4:279–292. [Google Scholar]
  • 14.CROWE JE, BUI PT, SIBER GR et ell: Cold-passaged, temperature-sensitive mutants of human respiratory virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine; (1995) 13(9):847–855. [DOI] [PubMed] [Google Scholar]
  • 15.MAASSAB HF, DEBORDE DC: Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine (1985) 3:355–369. [DOI] [PubMed] [Google Scholar]
  • 16.ALEXANDROVA GI: Live influenza vaccine in Russia. In: Options for the Control of Influenza III. Brown LE, Hampson AW, Webster RG (Eds), Elsevier, Amsterdam, The Netherlands (1996):122–128.
  • 17.BELSHE RB, NICHOL KL, BLACK SB et al.: Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. (2004) 39(7):920–927. [DOI] [PubMed] [Google Scholar]
  • 18.LI KS, GUAN Y, WANG J et al.: Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 430(6996):209–213. [DOI] [PubMed] [Google Scholar]
  • 19.WRIGHT PF, KARRON RA, BELSHE RB et al.: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. (2000) 182(5):1331–1342. [DOI] [PubMed] [Google Scholar]
  • 20.BELSHE RB, HISSOM FK: Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol (1982) 10(4):235–242. [DOI] [PubMed] [Google Scholar]
  • 21.CROWE JE, BUI PT, DAVIS AR, CHANOCK RM, MURPHY BR: A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine (1994) 12(9):783–790. [DOI] [PubMed] [Google Scholar]
  • 22.KIM HW, CANCHOLA JG, BRANDT CD et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol (1969) 89(4):422–434. [DOI] [PubMed] [Google Scholar]
  • 23.KAPIKIAN AZ, MITCHELL RH, CHANOCK RM, SHVEDOFF RA, STEWART CE: An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol (1969) 89(4):405–421. [DOI] [PubMed] [Google Scholar]
  • 24.FULGINITI VA, ELLER JJ, SIEBER OF et al.: Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol (1969) 89(4):435–448. [DOI] [PubMed] [Google Scholar]
  • 25.PERKINS JC, TUCKER DN, KNOPE HL et al.: Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am. J. Epidemiol (1969) 90(4):319–326. [DOI] [PubMed] [Google Scholar]
  • 26.GURWITH MJ, HORWITH GS, IMPELLIZZERI CA et ell.: Current use and future directions of adenovirus vaccine. Semin. Respir. Infect. (1989) 4(0299–303. [PubMed] [Google Scholar]
  • 27.MCINTOSH K: The SARS coronavirus: rapid diagnostics in the limelight. Clin. Chem; (2003) 49(6 Pt 1):845–846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.TANG L, ZHU Q, QIN E et ell: Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol; (2004) 23(6):391–394. [DOI] [PubMed] [Google Scholar]
  • 29.BERG P: Co-chairman's remarks: reverse genetics: directed modification of DNA for functional analysis. Gene (1993) 135:261–264. [DOI] [PubMed] [Google Scholar]
  • 30.RACANIELLO VR, BALTIMORE D: Cloned poliovirus complementary DNA is infectious in mammalian cells. Science (1981) 214(4523):916–919. [DOI] [PubMed] [Google Scholar]
  • 31.TANIGUCHI T, PALMIERI M, WEISSMANN C: 0j3 DNA-containing hybrid plasmids giving rise to 0j3 phage formation in the bacterial host. Nature (1978) 274(5668):223–228. [DOI] [PubMed] [Google Scholar]
  • 32.NEUMANN G, WHITT MA, KAWAOKA Y: A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J. Gen. Virol (2002) 83(Pt 11):2635–2662. [DOI] [PubMed] [Google Scholar]
  • 33.NAITO S, ISHIHAMA A: Function and structure of RNA polymerase from vesicular stomatitis virus. 1 Biol Chem. (1976) 251(14):4307–4314. [PubMed] [Google Scholar]
  • 34.EMERSON SU, YU Y: Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus. Virol (1975) 15(6):1348–1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.DE BP, BANERJEE AK: Requirements and functions of vesicular stomatitis virus L and NS proteins in the transcription process in vitro. Biochem. Biophys. Res. Commun. (1985) 126(1):40–49. [DOI] [PubMed] [Google Scholar]
  • 36.SCHNELL MJ, MEBATSION T, CONZELMANN KK: Infectious rabies viruses from cloned cDNA. EMBO J. (1994) 13(18):4195–4203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • ••This paper described the first rescue of a negative-stranded RNA virus entirely from cDNA.
  • 37.WYATT LS, MOSS B, ROZENBLATT S: Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology (1995) 210(1):202–205. [DOI] [PubMed] [Google Scholar]
  • 38.KATO A, SAKAI Y, SHIODA T et al.: Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells (1996) 1(6):569–579. [DOI] [PubMed] [Google Scholar]
  • 39.DURBIN AP HALL SL, SIEW jw et al. : Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology (1997) 235(2):323–332. [DOI] [PubMed] [Google Scholar]
  • •Outlines the procedure for the rescue of hPIV3 from cDNA.
  • 40.NEUMANN G, FELDMANN H, WATANABE S, LUKASHEVICH I, KAWAOKA Y: Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol (2002) 76(1):406–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.BRIDGEN A, ELLIOTT RM: Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. Proc. Natl Acad. Sci. USA (1996) 93(20:15400–15404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.FODOR E, DEVENISH L, ENGELHARDT OG et al: Rescue of influenza A virus from recombinant DNA. J. Virol (1999) 73(11):9679–9682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • ••One of the original papers describing therescue of influenza A virus entirely from cDNA.
  • 43.NEUMANN G, WATANABE T, ITO H et al.: Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA (1999) 96:9345–9350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • ••One of the original papers describing therescue of influenza A virus entirely from cDNA.
  • 44.COLLINS PL, HILL MG, CAMARGO E et al.: Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Nail. Acad. Sci. USA (1995) 92:11563–11567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • ••First paper describing the rescue of RSVfrom cDNA.
  • 45.JIN H, CLARKE D, ZHOU HZ et al: Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV Virology (1998) 251:206–214. [DOI] [PubMed] [Google Scholar]
  • 46.SCHICKLI JH, FLANDORFER A, NAKAYA T et al.: Plasmid-only rescue of influenza A virus vaccine candidates. Philos. Trans. R. Soc. Lond. B (2001) 356:1965–1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.NEUMANN G, WATANABE T, KAWAOKAY: Plasmid-driven formation of influenza virus-like particles. J. Wrol. (2000) 74(1):547–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.HOFFMANN E, MAHMOOD K, YANG C et al.: Rescue of influenza B virus from eight plasmids. Proc. Nail Acad. Sci. USA (2002) 99(17):11411–11416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.KAWANO M, KAITO M KOZUKAY et al.: Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain. Virology (2001) 284(1):99–112. [DOI] [PubMed] [Google Scholar]
  • 50.HOFFMAN MA, BANERJEE AK: An infectious clone of human parainfluenza virus type 3.1 Virol. (1997) 71(0:4272–4277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.BIACCHESI S, SKIADOPOULOS MH, TRAN KC et al.: Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 321(2):247–259. [DOI] [PubMed] [Google Scholar]
  • 52.HERFST S, DE GRAM M, SCHICKLI JH et al: Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA. j Virol (2004) 78(15):8264–8270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.KAPOOR QS, CHINNADURAI G: Method for introducing site-specific mutations into adenovirus 2 genome: construction of a small deletion mutant in VA-RNAI gene. Proc. Natl Acad. Sci. USA (1981) 78(4):2184–2188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.MIZUTANI S, COLONNO RJ: In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. Virol (1985) 56(2):628–632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.THIEL V, HEROLD J, SCHELLE B, SIDDELL SG: Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. 1 Gen. Virol (2001) 82\(Pt 6):1273–1281. [DOI] [PubMed] [Google Scholar]
  • 56.YOUNT B, CURTIS KM, FRITZ EA et al.: Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA (2003) 100(22):12995–13000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.TENG MN, COLLINS PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependant infectious particles. Wrol. (1998) 72(7):5707–5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.HOFFMANN E, NEUMANN G, KAWAOKA Y, HOBOM G, WEBSTER RG: A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA (2000) 97(11):6180–6113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.HOFFMANN E, NEUMANN G, HOBOM G, WEBSTER RG, Expert Opin. Biol. Ther (2005) 5(3) KAWAOKAY: Ambisense' approach for the generation of influenza A virus: yRNA and mRNA synthesis from one template. Virology; (2000) 267(2):310–317. [DOI] [PubMed] [Google Scholar]
  • 60.MUSTER T, SUBBARAO EK, ENAMI M, MURPHY BR, PALESE P: An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. Proc. Natl Acad. Sci. USA (1991) 88:5177–5181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.MURPHY BR, PARK EJ, GOTTLIEB P, SUBBARAO K: An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine (1997) 15:1372–1378. [DOI] [PubMed] [Google Scholar]
  • 62.PALESE P, GARCIA-SASTRE A: Influenza vaccines: present and future. J. Clin. Invest. (2002) 110(1):9–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.GARCIA-SASTRE A, EGOROV A, MATASSOV D et al.: Influenza A Virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 252:324–330. [DOI] [PubMed] [Google Scholar]
  • 64.TALON J, SALVATORE M, O'NEILL RE et al.: Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA; (2000) 97(8):4309–4314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.WATANABE T, WATANABE S, KIDA H, KAWAOKA Y: Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology (2002) 299(2):266–270. [DOI] [PubMed] [Google Scholar]
  • 66.CATCHPOLE AP, MINGAY LJ, FODOR E, BROWNLEE GG: Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene. J. Gen. Wrol. (2003) 84(3):507–515. [DOI] [PubMed] [Google Scholar]
  • 67.HOFFMANN E, KRAUSS S, PEREZ D, WEBBY R, WEBSTER RG: Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine (2002) 20(25-20:3165–3170. [DOI] [PubMed] [Google Scholar]
  • 68.KILBOURNE ED: Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ. (1969) 41:643–645. [PMC free article] [PubMed] [Google Scholar]
  • 69.GERDIL C: The annual production cycle for influenza vaccine. Vaccine (2003) 21:1776–1779. [DOI] [PubMed] [Google Scholar]
  • 70.AUDSLEY JM, TANNOCK GA: The role of cell culture vaccines in the next influenza pandemic. Expert Opin. Biol. Ther. (2004) 4(5):709–717. [DOI] [PubMed] [Google Scholar]
  • 71.OZAKI H, GOVORKOVA FA, LI C et al: Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J. Wrol. (2004) 78(4):1851–1857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.MONTAGNON BJ, FANGET B, NICOLAS AJ: The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. (1981) 47:55–64. [PubMed] [Google Scholar]
  • 73.MONTAGNON BJ, FANGET B, VINCENT-FALQUET JC: Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev. Infect. Dis; (1984) 6\(Suppl. 2):5341–5344. [DOI] [PubMed] [Google Scholar]
  • 74.QUIAMBAO BP, LANG J, VITAL S et al: Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines. Acta Trop. (2000) 75(1):39–52. [DOI] [PubMed] [Google Scholar]
  • 75.WANG XJ, LANG J, TAO XR et ell: Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China. Southeast Asian J. Trop. Med. Public Health; (2000) 31(2):287–294. [PubMed] [Google Scholar]
  • 76.KISTNER O, BARRETT PN, MUNDT W et al.: Development of a Vero cell-derived influenza whole virus vaccine. Dev. Biol. Stand. (1999) 98:101–110. [PubMed] [Google Scholar]
  • 77.KISTNER O, BARRETT PN, MUNDT W et al.: Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine (1998) 16(9-10):960–968. [DOI] [PubMed] [Google Scholar]
  • 78.BRUHL P, KERSCHBAUM A, KISTNER O et al.: Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine (2000) 19(9-10):1149–1158. [DOI] [PubMed] [Google Scholar]
  • 79.WEBBY RJ, WEBSTER RG: Are we ready for pandemic influenza? Science (2003) 302:1519–1522. [DOI] [PubMed] [Google Scholar]
  • 80.SUBBARAO K, KLIMOV A, KATZ J et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (1998) 279:393–396. [DOI] [PubMed] [Google Scholar]
  • 81.SUAREZ DL, PERDUE ML, COX N et al: Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. Virol (1998) 72:6678–6688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.SHORTRIDGE KF, ZHOU NN, GUAN Y et al.: Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology (1998) 252:331–342. [DOI] [PubMed] [Google Scholar]
  • 83.SUBBARAO K, CHEN H, SWAYNE D et al.: Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology (2003) 305(1):192–200. [DOI] [PubMed] [Google Scholar]
  • •Highlights an important role of reverse genetics in the preparation of vaccine candidates against highly pathogenic avian influenza.
  • 84.WEBBY RJ, PEREZ DR, COLEMAN JS et al.: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet (2004) 363(9415):1099–1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.BLOUNT RE JR, MORRIS JA, SAVAGE RE : Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. (1956) 92(3):544–549. [DOI] [PubMed] [Google Scholar]
  • 86.MURPHY BR, PRINCE GA, WALSH EE et al.: Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol (1986) 24(2):197–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.OPENSHAW PJ, CULLEY FJ, OLSZEWSKA W: Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine (2002) 20:S27–S31. [DOI] [PubMed] [Google Scholar]
  • 88.HANCOCK GE, SPEELMAN DJ, HEERS K et al.: Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol (1996) 70(11):7783–7791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.GRAHAM BS, HENDERSON GS, TANG YW et al.: Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. Immunol (1993) 151(4):2032–2040. [PubMed] [Google Scholar]
  • 90.CONNORS M, COLLINS PL, FIRESTONE CY et al: Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine (1992) 10(7):475–484. [DOI] [PubMed] [Google Scholar]
  • 91.MURPHY BR, SOTNIKOV AV, LAWRENCE LA, BANKS SM, PRINCE Gk Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine (1990) 8(5):497–502. [DOI] [PubMed] [Google Scholar]
  • 92.DUDAS RA, KARRON RA: Respiratory syncytial virus vaccines. Clin. Microbiol Rev. (1998) 11(3):430–439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.COLLINS PL, WHITEHEAD SS, BUKREYEV A et al.: Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res. (1999) 54:423–451. [DOI] [PubMed] [Google Scholar]
  • 94.TENG MN, COLLINS PL: Altered growth characteristics of recombinant respiratory syncytial virus which do not produce N52 protein. J. Wrol. (1999) 73(1):466–473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.WHITEHEAD SS, BUKREYEV A, TENG MN et al.: Recombinant respiratory syncytial virus bearing a deletion of either the N52 or SH gene is attenuated in chimpanzees. j Virol (1999) 73(4):3438–3442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.TENG MN, -WHITEHEAD SS, COLLINS PL: Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology (2001) 289:283–296. [DOI] [PubMed] [Google Scholar]
  • 97.TENG MN, -WHITEHEAD SS, BERMINGHAM A et al: Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol (2000) 74(19):9317–9321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.KARRON RA, BUONAGURIO DA, GEORGUIS AF et al: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA (1997) 94:13961–13966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.JIN H, CHENG X, ZHOU HZ, LI S, SEDDIQUI A: Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. Wrol. (2000) 74(1):74–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.JIN H, ZHOU H, CHENG X et al.: Recombinant respiratory syncytial viruses with deletions in the NS1, N52, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology (2000) 273(1):210–218. [DOI] [PubMed] [Google Scholar]
  • 101.JIN H, CHENG X, TRAINA-DORGE VL et al: Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine (2003) 21(25-26):3647–3652. [DOI] [PubMed] [Google Scholar]
  • 102.BERMINGHAM A, COLLINS PL: The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Nail. Acad. Sci. USA (1999) 96(20):11259–11264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.KARRON RA, BUONAGURIO DA, GEORGIU AF et al.: Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA (1997) 94(25):13961–13966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.COLLINS PL, MURPHY BR: Respiratory syncytial virus: Reverse genetics and vaccine strategies. Virology (2002) 296:204–211. [DOI] [PubMed] [Google Scholar]
  • 105.BUKREYEV A, BELYAKOV IM, BERZOFSKY JA, MURPHY BR, COLLINS PL: Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol (2001) 75(24):12128–12140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.CHIN J, MAGOFFIN RL, SHEARER LA, SCHIEBLE JH, LENNETTE EH: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol (1969) 89(4):449–463. [DOI] [PubMed] [Google Scholar]
  • 107.HALL SL, MURPHY BR, VAN WYKE COELINGH KL: Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus. Vaccine (1991) 9(9):659–667. [DOI] [PubMed] [Google Scholar]
  • 108.LEHMAN DJ, ROOF LL, BRIDEAU RJ et al.: Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines. J. Gen. Virol (1993) 74(Pt 3):459–469. [DOI] [PubMed] [Google Scholar]
  • 109.VAN WYKE COELINGH KL, WINTER CC, TIERNEY EL, LONDON WT, MURPHY BR : Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J. Infect. Dis. (1988) 157(4):655–662. [DOI] [PubMed] [Google Scholar]
  • 110.KARRON RA, WRIGHT PF, HALL SL et al.: A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. (1995) 171(5):1107–1114. [DOI] [PubMed] [Google Scholar]
  • 111.HALL SL, STOKES A, TIERNEY EL et al.: Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. (1992) 22(3):173–184. [DOI] [PubMed] [Google Scholar]
  • 112.KARRON RA, BELSHE RB, WRIGHT PF et al.: A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. j (2003) 22(5):394–405. [DOI] [PubMed] [Google Scholar]
  • 113.TAO T, SKIADOPOULOS MH, DAVOODI F et al.: Construction of alive-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Vaccine (2001) 19(27):3620–3631. [DOI] [PubMed] [Google Scholar]
  • 114.TAO T, DAVOODI F, CHO C et al: A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine (2000) 18:1359–1366. [DOI] [PubMed] [Google Scholar]
  • 115.TAO T, SKIADOPOULOS MH, DURBIN AP et al.: A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine (1999) 17(9-10):1100–1108. [DOI] [PubMed] [Google Scholar]
  • 116.DURBIN AP, MCAULIFFE JM, COLLINS PL, MURPHY BR: Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology (1999) 261(2):319–330. [DOI] [PubMed] [Google Scholar]
  • 117.BAILLY JE, MCAULIFFE JM, DURBIN AP et al.: A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J. Virol (2000) 74(7):3188–3195. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Expert Opinion on Biological Therapy are provided here courtesy of Taylor & Francis

RESOURCES